Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Rounding out Neurocrine’s sales was Crenessity, its treatment for congenital adrenal hyperplasia, which reeled in $98 million. Neurocrine made another move to diversify its assets earlier this year, ...

Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...

Neurocrine BiosciencesNBIX shares rose late Tuesday after its bread-and-butter drug, Ingrezza, beat third-quarter ...

Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

Crinetics Pharma (($CRNX)) announced an update on their ongoing clinical study. Study Overview: Crinetics Pharmaceuticals is conducting a study ...

Analysts are estimating that Neurocrine Biosciences will report an earnings per share (EPS) of $1.87. Neurocrine Biosciences ...

Every child deserves a healthy start in life—and for many Filipino families, that begins with a small prick on a newborn’s ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a ...

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...

Classic congenital adrenal hyperplasia (CAH) is a condition that is passed down in families. It is a serious condition that can be deadly if not treated. One of the treatments for classic CAH is ...

People with classic congenital adrenal hyperplasia (CAH) often experience fertility issues, but hormone-balancing treatment can help. This rare genetic disorder is most often caused by a ...